Asco 2023 movers – maintaining the momentum
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.